Avobis Bio

Cell/regenerative therapy (private)

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Implantable cell/biomaterial constructCell therapy
Inflammatory Bowel Disease
Crohn's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2025Topline resultAVB-114STOMP2 Phase 2 (NCT04847739) primary analysis: combined remission 45.8% with AVB-114 vs 8.3% with standard of care
US · Avobis Bio · Source ↗

Financial reports

No financial reports recorded.